glp 1 agonists and inflammation Central glucagon-like peptide receptor activation inhibits Toll-like receptor agonist-induced inflammation: Cell Metabolism The Unstoppable Rise of GLP-1

Dulaglutide ( n = 1, REWIND [19])

Acta Neurol Scand 2010

Experience with oral GLP1 use in diabetes has highlighted this disconnect: tablets are often not viewed as premium products, and the scientific and manufacturing innovation required to enable the oral delivery of biologics can be underappreciated at times reduced to just a pill. This perception gap may pose commercial challenges, especially when oral therapies are priced alongside injectable alternatives

In contrast, GLP-1RAs provide prolonged systemic effects, making them well-suited for managing chronic conditions like T2D and obesity

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established